Spotlight on ...

Spotlight on ...

Oncology

Acute Lymphoblastic Leukaemia highjacks a neural mechanism to invade the CNS

Acute Lymphoblastic Leukaemia (ALL) most often metastasise to organs such as the spleen and lymph nodes, but also to the Central Nervous System (CNS). Here, Yao et al show that ALL cells infiltrate the CNS not by breaching the blood-brain barrier, but by hijacking the neural migratory pathways.

Gene expression profiles from plucked scalp hair to assess pharmacodynamic biomarkers following treatment of advanced solid tumors with a novel anti-cancer stem cell Wnt inhibitor

Wnt signaling pathway genes are crucial for cell fate determination and cell polarity during development. Ipafricept (OMP-54F28) is a first in class recombinant fusion protein producing a truncated decoy receptor that binds to a cystine-rich region of Wnt ligand and as a result it blocks the activation of the Wnt signaling. Here the authors described the results of a phase 1 first in-human clinical trial.

Two recent papers highlight the importance of tumour microenvironment on cancer cell stemness

Two recent papers demonstrate the importance of the tumour microenvironment on its progression through in vitro co-culture. The authors in one paper show that M2 macrophages increase the stem cell capacity of an ovarian cancer cell line, whilst in the other fibroblasts increase the stemness of a lung carcinoma cell line. They highlight the importance of considering the tumour microenvironment in in vitro experimentation, and also reveal potential new therapeutic targets.

CAR-T Cells in cancer Therapy

Summary of a paper reporting an unusually delayed response from one patient during a clinical trial in CLL using CAR T-cells targeted to CD-19 that may shed light on some of the mechanisms determining persistence of CAR T-cells and their clinical outcome.

Can changes to gut microbiota affect the efficacy of chemotherapies?

Can changes to gut microbiota affect the efficacy of chemotherapies?

Oncogenic JAK2V617F causes PD‑L1 expression, mediating immune escape in myeloproliferative neoplasm

Oncogenic JAK2V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms

Targeting breast cancer with Hsp70‑aptamer‑guided nanoparticles with chemotherapeutic payloads

Targeting breast cancer with Hsp70-Aptamer-guided nanoparticles with chemotherapeutic payloads

CAR-T Cells: Engineering Immune Cells to Treat Cancers

For many years surgery, chemotherapy and radiation therapy have been the foundations of cancer treatment. Over the last two decades, targeted therapies have cemented themselves as standard treatments for many cancers and over the past several years, immunotherapy therapies that enlist and strengthen the power of a patient’s immune system to attack tumours has emerged.

JAK2, a novel therapeutic target in lung adenocarcinoma?

The field of personalised medicine to provide understanding of the molecular basis of disease is constantly growing. Multiple signalling pathways have been identified that associate with malignant transformation. However, the vast majority of lung cancer patients have no known driver genes detected, and they are still treated with standard cytotoxic chemotherapy.

Platelets are major suppressors of T cell function

We currently offer validated models to address immune function in tumour bearing mice. Our detailed flow cytometric expertise can further assess the identity of tumour infiltrating and peripheral cell populations such as CD8+ T cells, MDCSs and regulatory T cells, by surface identification of key molecules, or the intracellular mediators they express (cytokines, transcription factors).

Development of a Signature of Aberrant Myc Transcription has Prognostic Value in Evaluating Novel Myc-Targeted Therapies

Altered expression of transcription factors are key indicators in cancer progression in functions such as proliferation and differentiation, angiogenesis and apoptosis. A significant proportion of cancers are driven by mutations in these networks, including Wnt/β-catenin, Ras/MAPK and Myc

New biomarker/therapeutic target in AML

The field of personalised medicine to provide understanding of the molecular basis of disease and the mechanism of action of chemotherapeutic drugs is constantly growing. A recent study carried out by Schneider et al has highlighted several interesting facts.

The Tumor Microenvironment Represses T Cell Mitochondrial Biogenesis to Drive Intratumoral T Cell Metabolic Insufficiency and Dysfunction

we currently offer 3 models to address the immune response in tumour bearing mice. Metabolic and mitochondrial function of T cells can be assessed by flow cytometry. Our detailed flow cytometric expertise can further assess the identity of tumour infiltrating and peripheral cell populations, by surface identification of key molecules, or the intracellular mediators they express (cytokines, transcription factors).

Novel drug prevents AML cells from hiding

It’s generally accepted that leukaemic stem cells can lodge in the protective bone marrow niche, thereby escaping chemotherapy and with time potentially initiate a relapse.